Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19 (OPV-NA831)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04540185
Recruitment Status : Enrolling by invitation
First Posted : September 7, 2020
Last Update Posted : September 9, 2020
Sponsor:
Collaborator:
Biomed Industries, Inc.
Information provided by (Responsible Party):
NeuroActiva, Inc.

Tracking Information
First Submitted Date  ICMJE September 4, 2020
First Posted Date  ICMJE September 7, 2020
Last Update Posted Date September 9, 2020
Estimated Study Start Date  ICMJE November 1, 2020
Estimated Primary Completion Date November 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 4, 2020)
  • Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of OPV with or without NA-831 [ Time Frame: Time Frame: Day 29 (second dose) up to Day 365 (1 years after second dose) ]
    Number of participants infected with Covid-19 after second dose
  • Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal [ Time Frame: Time Frame: Up to Day 365 (1 years after second dose) ]
    Number of participants with adverse events
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 4, 2020)
  • Number of Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of OPV with or without NA-831 [ Time Frame: Time Frame: Day 29 (second dose) up to Day 365 (1 years after second dose) ]
    Clinical signs indicative of severe COVID-19 as predefined for the study.
  • Number of Participants with a First Occurrence of COVID-19 Starting 14 days after Second Dose of OPV with or without NA-831 or Placebo regardless of evidence of prior SARS-CoV-2 Infection [ Time Frame: Time Frame: Day 29 (second dose) up to Day 759 (2 years after second dose) ]
    Clinical signs indicative of COVID-19 and SARS-CoV-2 infection as predefined for the study.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
Official Title  ICMJE A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19
Brief Summary In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.
Detailed Description

Early clinical studies showed that besides protecting against poliomyelitis, oral polio vaccine (OPV) reduced the number of other viruses that could be isolated from immunized children, compared with placebo recipients.

Both poliovirus and coronavirus are positive-strand RNA viruses; therefore, it is likely that they may induce and be affected by common innate immunity mechanisms. Recent reports indicate that COVID-19 may result in suppressed innate immune responses. Stimulation by live attenuated oral polio vaccines could increase resistance to infection by the causal virus, severe acute respiratory syndrome-SARS-CoV-2.

It has been discovered that SARS-CoV-2 viruses (Covid-19) can directly invade the nervous system of patients, instead of injuring the nervous system through the immune response. Increasing evidence suggests that infection with SARS-CoV-2 causes neurological deficits in a substantial proportion of affected patients. It was observed that patients surviving COVID-19 are at high risk for subsequent development of neurological disease and in particular Alzheimer's disease.

NA-831 is a new neuroprotective and neurogenesis drug that has been demonstrated its promising safety and efficacy in Phase 2A for the treatment of early onset ofAlzheimer's disease. NA-831 in oral formulation is well tolerated NA-831 with no adverse effects.

The Phase 3 clinical trial will evaluate the safety and efficacy of OPV with and without NA-831 versus placebo.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Parallel assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE
  • Covid19
  • SARS (Severe Acute Respiratory Syndrome)
  • SARS-CoV Infection
  • SARS-CoV-2
Intervention  ICMJE
  • Biological: Biological: oral polio vaccine
    Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
    Other Name: Oral Polio Vaccine (OPV)
  • Biological: Comparable Placebo
    Placebo of a vaccine 0.1 ml administered orally on a sugar lump
    Other Name: Placebo comparator
  • Drug: NA-831
    Drug: NA-831 30 mg of NA-831 in a capsule administered orally
    Other Name: NA-81 is a neuroprotective drug
  • Drug: Comparable Placebo of drug
    Placebo 30 mg in a capsule administered orally
    Other Name: Placebo comparator
  • Combination Product: Combination of oral polio vaccine and NA-831
    Combination of biological: Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump and drug NA-831 30 mg in a capsule administered orally
    Other Name: OPV and Drug combination
  • Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of drug
    Combination of biological placebo 0.1 ml administered orally on a sugar lump and drug placebo 30 mg in a capsule administered orally
    Other Name: Placebo Comparator
Study Arms  ICMJE
  • Experimental: Standard dose bivalent oral polio vaccine
    Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump
    Intervention: Biological: Biological: oral polio vaccine
  • Placebo Comparator: Comparable Placebo- 0.10 mg/kg
    Saline administered orally on a sugar lump
    Intervention: Biological: Comparable Placebo
  • Experimental: Standard dose of NA-831
    Drug: neuroprotection NA-831 30 mg of NA-831in a capsule administered orally
    Intervention: Drug: NA-831
  • Placebo Comparator: Comparable Placebo- 30mg
    30 mg of placebo in a capsule administered orally
    Intervention: Drug: Comparable Placebo of drug
  • Experimental: Standard dose of bivalent OPV and NA-831
    Biological: oral polio vaccine Bivalent OPV (GSK), 0.1 ml administered orally on a sugar lump Plus 30 mg of neuroprotection drug NA-831 in a capsule administered orally
    Intervention: Combination Product: Combination of oral polio vaccine and NA-831
  • Placebo Comparator: Comparable Placebo
    Placebo of a vaccine administered orally on a sugar lump Plus 30 mg of a placebo in a capsule administered orally
    Intervention: Combination Product: Comparable Placebo of Oral Polio Vaccine and Placebo of drug
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Enrolling by invitation
Estimated Enrollment  ICMJE
 (submitted: September 4, 2020)
3600
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2022
Estimated Primary Completion Date November 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participants who are at high risk of SARS-CoV-2 infection, defined as adults whose locations or circumstances put them at appreciable risk of exposure to SARS-CoV-2 and COVID-19.
  • Understands and agrees to comply with the study procedures and provides written informed consent.
  • Able to comply with study procedures based on the assessment of the Investigator.
  • Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy) or postmenopausal (defined as amenorrhea for ≥12 consecutive months prior to Screening without an alternative medical cause). A follicle-stimulating hormone (FSH) level may be measured at the discretion of the Investigator to confirm postmenopausal status.
  • Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria:

    • Has a negative pregnancy test at Screening and on the day of the first dose (Day 1).
    • Has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose (Day 1).
    • Has agreed to continue adequate contraception through 3 months following the second dose on Day 29.
    • Is not currently breastfeeding.
  • Male participants engaging in activity that could result in pregnancy of sexual partners must agree to practice adequate contraception and refrain from sperm donation from the time of the first dose and through 3 months after the second dose.
  • Healthy adults or adults with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.

Exclusion Criteria:

  • Is acutely ill or febrile 72 hours prior to or at Screening. Fever is defined as a body temperature ≥38.0°C/100.4°F. Participants meeting this criterion may be rescheduled within the relevant window periods. Afebrile participants with minor illnesses can be enrolled at the discretion of the Investigator.
  • Is pregnant or breastfeeding.
  • Known history of SARS-CoV-2 infection.
  • Prior administration of an investigational coronavirus (SARS-CoV, Middle East Respiratory Syndrome [MERS]-CoV) vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19.
  • Demonstrated inability to comply with the study procedures.
  • An immediate family member or household member of this study's personnel.
  • History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine.
  • Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy.
  • Has received or plans to receive a vaccine within 28 days prior to the first dose (Day 1) or plans to receive a non-study vaccine within 28 days prior to or after any dose of investigational product (except for seasonal influenza vaccine).
  • Has participated in an interventional clinical study within 28 days prior to the day of enrollment.
  • Immunosuppressive or immunodeficient state, including human immunodeficiency virus (HIV) infection, asplenia, and recurrent severe infections.
  • Has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids ≥20 milligram (mg)/day of prednisone equivalent). Topical tacrolimus is allowed if not used within 14 days prior to Screening.
  • Has received systemic immunoglobulins or blood products within 3 months prior to the day of Screening.
  • Has donated ≥450 milliliters (mL) of blood products within 28 days prior to Screening.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE New Zealand,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04540185
Other Study ID Numbers  ICMJE OPV-NA831
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: We plan to share the Study Protocol and other information if needed
Supporting Materials: Study Protocol
Time Frame: 90 days after completion of the study
Access Criteria: To be verified and determined at a later date
Responsible Party NeuroActiva, Inc.
Study Sponsor  ICMJE NeuroActiva, Inc.
Collaborators  ICMJE Biomed Industries, Inc.
Investigators  ICMJE
Study Director: Lloyd Tran, PhD Coronavirus Research Institute
PRS Account NeuroActiva, Inc.
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP